| scholarly article | Q13442814 |
| P50 | author | Dheerendra Pandey | Q87028055 |
| P2093 | author name string | Amit A Joharapurkar | |
| Mukul R Jain | |||
| Vishal J Patel | |||
| Maulik S Patel | |||
| Hiren M Patel | |||
| Rajesh H Bahekar | |||
| Samadhan G Kshirsagar | |||
| Brijesh K Sutariya | |||
| P2860 | cites work | Histological changes of kidney in diabetic nephropathy | Q26773633 |
| Rodent models of diabetic nephropathy: their utility and limitations | Q28073885 | ||
| Diabetes and nephropathy | Q35108195 | ||
| GLP-1 based therapeutics: simultaneously combating T2DM and obesity. | Q35200252 | ||
| Mouse Models of Diabetes, Obesity and Related Kidney Disease | Q36118363 | ||
| The cardiovascular effects of GLP-1 receptor agonists | Q36368998 | ||
| Obesity and diabetic kidney disease | Q36515043 | ||
| Advances in murine models of diabetic nephropathy | Q36971495 | ||
| Obesity, diabetes, and chronic kidney disease | Q37078515 | ||
| FGF21: a novel prospect for the treatment of metabolic diseases. | Q37428992 | ||
| Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II. | Q37664101 | ||
| The metabolic actions of glucagon revisited | Q37801277 | ||
| Pathophysiology, prevention and management of chronic kidney disease in the hypertensive patient with diabetes mellitus. | Q37861885 | ||
| Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. | Q37871339 | ||
| Structural renal changes in obesity and diabetes | Q38078544 | ||
| The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems | Q38174279 | ||
| Effect of GLP-1 based therapies on diabetic dyslipidemia | Q38226698 | ||
| Therapeutic potential of coagonists of glucagon and GLP-1. | Q38261427 | ||
| Lack of glucagon receptor signaling and its implications beyond glucose homeostasis | Q38310899 | ||
| Adiponectin gene therapy of streptozotocin-induced diabetic mice using hydrodynamic injection. | Q40080559 | ||
| The effect of short-term glucagon infusion on kidney function in normal man | Q40819458 | ||
| An update on diabetic kidney disease, oxidative stress and antioxidant agents | Q42094755 | ||
| A new glucagon and GLP-1 co-agonist eliminates obesity in rodents | Q43756107 | ||
| Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice | Q44070536 | ||
| 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. | Q45083258 | ||
| Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. | Q47197056 | ||
| Coagonist of GLP-1 and glucagon receptor ameliorates development of non-alcoholic fatty liver disease. | Q47650840 | ||
| Reversal of lesions of diabetic nephropathy after pancreas transplantation | Q47879758 | ||
| Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model. | Q50130980 | ||
| Coagonist of GLP-1 and glucagon receptors ameliorates non-alcoholic fatty liver disease. | Q50181163 | ||
| Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice | Q50225628 | ||
| Betulinic acid, isolated from the leaves of Syzygium cumini (L.) Skeels, ameliorates the proteinuria in experimental membranous nephropathy through regulating Nrf2/NF-κB pathways | Q50888865 | ||
| Betanin, isolated from fruits of Opuntia elatior Mill attenuates renal fibrosis in diabetic rats through regulating oxidative stress and TGF-β pathway. | Q51174940 | ||
| Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. | Q51475764 | ||
| Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters. | Q51733343 | ||
| Chronic renal diseases as a public health problem: epidemiology, social, and economic implications | Q57702843 | ||
| Effects of glucagon on renal function in man | Q78279886 | ||
| The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential | Q86577408 | ||
| Obesity and Kidney Disease: Hidden Consequences of the Epidemic | Q89223478 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 6 | |
| P921 | main subject | obesity | Q12174 |
| glucagon | Q28163629 | ||
| P304 | page(s) | 80-91 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | World journal of diabetes | Q27723539 |
| P1476 | title | Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus | |
| P478 | volume | 9 |
Search more.